Cargando…

High Immunoexpression of COX-2 as a Metastatic Risk Factor in ccRCC without PD-L1 Involvement

INTRODUCTION: Clear cell renal cell carcinoma (ccRCC) is the most lethal type of malignancy of the urinary tract system as it is resistant to chemotherapy and radiation and has a survival rate of less than 5% in cases of metastasis. Inflammation plays an essential role in the metastasis of ccRCC. Cy...

Descripción completa

Detalles Bibliográficos
Autores principales: Suryanti, Sri, Agustina, Hasrayati, Aziz, Afiati, Yulianti, Herry, Suryawathy, Bethy, Putri, Lestari
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8403071/
https://www.ncbi.nlm.nih.gov/pubmed/34466408
http://dx.doi.org/10.2147/RRU.S324510
_version_ 1783745941789999104
author Suryanti, Sri
Agustina, Hasrayati
Aziz, Afiati
Yulianti, Herry
Suryawathy, Bethy
Putri, Lestari
author_facet Suryanti, Sri
Agustina, Hasrayati
Aziz, Afiati
Yulianti, Herry
Suryawathy, Bethy
Putri, Lestari
author_sort Suryanti, Sri
collection PubMed
description INTRODUCTION: Clear cell renal cell carcinoma (ccRCC) is the most lethal type of malignancy of the urinary tract system as it is resistant to chemotherapy and radiation and has a survival rate of less than 5% in cases of metastasis. Inflammation plays an essential role in the metastasis of ccRCC. Cyclooxygenase-2 (COX-2) is an inflammatory protein that affects the processes of carcinogenesis, invasion, migration, metastasis, and angiogenesis. COX-2 can modulate programmed death ligand-1 (PD-L1) expression and play a role in immune evasion, meaning that tumor cells are able to escape the body’s immune response and more easily metastasize. PURPOSE: This study aims to determine the role of COX-2 and PD-L1 in the occurrence of ccRCC metastases. MATERIALS AND METHODS: This study is an observational analytical study, which employed a cross-sectional approach to examine the paraffin block samples of 40 ccRCC cases from Dr. Hasan Sadikin Hospital Bandung, Indonesia, between 2014 and 2021. Immunoexpression was measured using immunohistochemical staining for COX-2 in tumor cells and for PD-L1 in immune cells. PD-L1 calculation was measured using Qupath 0.2.3. digital software. Metastatic data were obtained using radiological imaging and pathological examinations. Meanwhile, the data were analyzed using the chi-square test for COX-2 and Fischer’s exact test for PD-L1. RESULTS: The research results revealed a significant association between COX-2 and the occurrence of metastases in ccRCC (p=0.001) with a prevalence odds ratio of 10.28. Positive PD-L1 immunoexpression of the immune cells (≥1%) was found in 14% (3/21) of the metastatic group and 5% (1/19) of the non-metastatic group (p=0.607). There was no association between COX-2 and PD-L1 immunoexpression (p=0.278). CONCLUSION: This study shows that metastases in ccRCC patients are ten times as likely to be associated with high COX-2 immunoexpression than low COX-2 immunoexpression. COX-2 plays a role in the process of ccRCC metastasis without PD-L1 involvement.
format Online
Article
Text
id pubmed-8403071
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-84030712021-08-30 High Immunoexpression of COX-2 as a Metastatic Risk Factor in ccRCC without PD-L1 Involvement Suryanti, Sri Agustina, Hasrayati Aziz, Afiati Yulianti, Herry Suryawathy, Bethy Putri, Lestari Res Rep Urol Original Research INTRODUCTION: Clear cell renal cell carcinoma (ccRCC) is the most lethal type of malignancy of the urinary tract system as it is resistant to chemotherapy and radiation and has a survival rate of less than 5% in cases of metastasis. Inflammation plays an essential role in the metastasis of ccRCC. Cyclooxygenase-2 (COX-2) is an inflammatory protein that affects the processes of carcinogenesis, invasion, migration, metastasis, and angiogenesis. COX-2 can modulate programmed death ligand-1 (PD-L1) expression and play a role in immune evasion, meaning that tumor cells are able to escape the body’s immune response and more easily metastasize. PURPOSE: This study aims to determine the role of COX-2 and PD-L1 in the occurrence of ccRCC metastases. MATERIALS AND METHODS: This study is an observational analytical study, which employed a cross-sectional approach to examine the paraffin block samples of 40 ccRCC cases from Dr. Hasan Sadikin Hospital Bandung, Indonesia, between 2014 and 2021. Immunoexpression was measured using immunohistochemical staining for COX-2 in tumor cells and for PD-L1 in immune cells. PD-L1 calculation was measured using Qupath 0.2.3. digital software. Metastatic data were obtained using radiological imaging and pathological examinations. Meanwhile, the data were analyzed using the chi-square test for COX-2 and Fischer’s exact test for PD-L1. RESULTS: The research results revealed a significant association between COX-2 and the occurrence of metastases in ccRCC (p=0.001) with a prevalence odds ratio of 10.28. Positive PD-L1 immunoexpression of the immune cells (≥1%) was found in 14% (3/21) of the metastatic group and 5% (1/19) of the non-metastatic group (p=0.607). There was no association between COX-2 and PD-L1 immunoexpression (p=0.278). CONCLUSION: This study shows that metastases in ccRCC patients are ten times as likely to be associated with high COX-2 immunoexpression than low COX-2 immunoexpression. COX-2 plays a role in the process of ccRCC metastasis without PD-L1 involvement. Dove 2021-08-24 /pmc/articles/PMC8403071/ /pubmed/34466408 http://dx.doi.org/10.2147/RRU.S324510 Text en © 2021 Suryanti et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Suryanti, Sri
Agustina, Hasrayati
Aziz, Afiati
Yulianti, Herry
Suryawathy, Bethy
Putri, Lestari
High Immunoexpression of COX-2 as a Metastatic Risk Factor in ccRCC without PD-L1 Involvement
title High Immunoexpression of COX-2 as a Metastatic Risk Factor in ccRCC without PD-L1 Involvement
title_full High Immunoexpression of COX-2 as a Metastatic Risk Factor in ccRCC without PD-L1 Involvement
title_fullStr High Immunoexpression of COX-2 as a Metastatic Risk Factor in ccRCC without PD-L1 Involvement
title_full_unstemmed High Immunoexpression of COX-2 as a Metastatic Risk Factor in ccRCC without PD-L1 Involvement
title_short High Immunoexpression of COX-2 as a Metastatic Risk Factor in ccRCC without PD-L1 Involvement
title_sort high immunoexpression of cox-2 as a metastatic risk factor in ccrcc without pd-l1 involvement
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8403071/
https://www.ncbi.nlm.nih.gov/pubmed/34466408
http://dx.doi.org/10.2147/RRU.S324510
work_keys_str_mv AT suryantisri highimmunoexpressionofcox2asametastaticriskfactorinccrccwithoutpdl1involvement
AT agustinahasrayati highimmunoexpressionofcox2asametastaticriskfactorinccrccwithoutpdl1involvement
AT azizafiati highimmunoexpressionofcox2asametastaticriskfactorinccrccwithoutpdl1involvement
AT yuliantiherry highimmunoexpressionofcox2asametastaticriskfactorinccrccwithoutpdl1involvement
AT suryawathybethy highimmunoexpressionofcox2asametastaticriskfactorinccrccwithoutpdl1involvement
AT putrilestari highimmunoexpressionofcox2asametastaticriskfactorinccrccwithoutpdl1involvement